Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Therapeutic Strategies for COVID-19 Patients: An Update

Tue Mar 5 00:09:55 2024

(2022) Therapeutic Strategies for COVID-19 Patients: An Update. Infectious disorders drug targets. pp. 10-21. ISSN 2212-3989 (Electronic) 1871-5265 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/35319396

Abstract

The novel coronavirus SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread, causing a global pandemic that infected more than 444 million people, resulting in severe social and economic ramifications, and claimed more than 6,010,000 lives by March 5, 2022. The pandemic attracted global attention with consequential multiple economic, social, and clinical studies. Among causes of poor clinical outcomes of the disease are therapeutic challenges, leading to spirals of studies in search of better therapeutic alternatives. Despite the worsening circumstances of the pandemic, no drug has yet shown remarkable efficacy in the clinical management of COVID-19 patients in large-scale trials. Many potential therapeutic strategies, including the use of nucleotide analogs, chloroquine phosphate, arbidol, protease inhibitors (lopinavir/ritonavir), plasma, monoclonal antibodies, plastic antibodies based on molecularly imprinted polymers (MIPs), traditional Chinese medicine (TCM), nanomaterials, vaccine, and mesenchymal stem cells (MSCs), have emerged with various degrees of successes. Remdesivir and dexamethasone have now been licensed based on the results of randomized controlled trials. Baricitinib, the Janus kinase (JAK) 1/2 inhibitor, is also an attractive candidate due to its properties as a potent anti-inflammatory agent and its hypothesized offtarget antiviral effects against SARS-CoV-2. Besides, human plasma from recovered COVID-19 patients is theoretically expected to be safe and effective for both therapy and post-exposure prophylaxis. In light of the literature, the correlation between the reduction of C5aR1/C5aR2 and the IL6-IL6R axis, using the available anti-IL6R mAb would be crucial. Moreover, MSCs are a potential therapeutic choice for patients with COVID-19 pneumonia. The coronavirus spike (S) protein that mediates the process of the infection via binding of host cells to the virus receptor is an essential focus for vaccine development. Importantly, with the number of patients increasing daily, there is an urgent need for effective therapeutic intervention. In this review, we expatiated on several strategies deployed for the treatment of COVID-19 infection.

Item Type: Article
Creators:
CreatorsEmail
Getso, M. I.UNSPECIFIED
Etemadi, S.UNSPECIFIED
Raissi, V.UNSPECIFIED
Mohseni, M.UNSPECIFIED
Mohseni, M. S.UNSPECIFIED
Raeisi, F.UNSPECIFIED
Raiesi, O.UNSPECIFIED
Keywords: Antiviral Agents *covid-19 Humans Pandemics Protease Inhibitors SARS-CoV-2 Covid-19 mesenchymal stem cells therapeutic strategies treatment vaccine
Divisions:
Page Range: pp. 10-21
Journal or Publication Title: Infectious disorders drug targets
Journal Index: Pubmed
Volume: 22
Number: 6
Identification Number: https://doi.org/10.2174/1871526522666220322145729
ISSN: 2212-3989 (Electronic) 1871-5265 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4089

Actions (login required)

View Item View Item